Regulatory, legislative, and policy updates with anticoagulant use

Thromboembolism afflicts millions of patients annually in the United States and is associated with a significant cost burden. Recent advances in oral anticoagulation have provided clinicians with more options for management of these diseases. Accordingly, regulatory, legislative, and policy-making o...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of thrombosis and thrombolysis Vol. 39; no. 3; pp. 273 - 287
Main Authors:	Fanikos, John, Buckley, Leo F., Aldemerdash, Ahmed, Terry, Kimberly J., Piazza, Gregory, Connors, Jean M., Goldhaber, Samuel Z.
Format:	Journal Article
Language:	English
Published:	Boston Springer US 01-04-2015 Springer Nature B.V
Subjects:	Administration, Oral Anticoagulants - therapeutic use Cardiology Hematology Humans Legislation, Drug Medicine Medicine & Public Health Thromboembolism - drug therapy United States United States Stroke Anticoagulation Health policy Regulatory affairs Venous thromboembolism
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Thromboembolism afflicts millions of patients annually in the United States and is associated with a significant cost burden. Recent advances in oral anticoagulation have provided clinicians with more options for management of these diseases. Accordingly, regulatory, legislative, and policy-making organizations have intervened with the aim of improving patient outcomes, ensuring patient safety, and reducing costs. There have been a number of recent developments in surveillance, litigation, and regulatory oversight that clinicians should recognize. In this review article we summarize key updates related to the management of anticoagulant therapy as it relates to thrombosis prevention and treatment.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0929-5305 1573-742X
DOI:	10.1007/s11239-015-1198-2